BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
04. Dezember 2024 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
07. Oktober 2024 07:58 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, leading cell and gene therapy consultancy, today unveils the Initiative for Certification of Manufacturing Capabilities: ICMC™
Dark Horse Consulting Group Acquires BioTechLogic, Inc.
03. Oktober 2024 11:18 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, the global leader in cell and gene therapy consulting, is delighted to announce the acquisition of BioTechLogic, Inc.
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
20. Juni 2024 08:45 ET
|
ClearPoint Neuro, Inc.
ClearPoint® Navigation System to be used for all enrolled patients in Aspen's ASPIRO Parkinson's cell therapy clinical trial
Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
15. April 2024 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13. März 2024 07:00 ET
|
BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
05. Januar 2024 16:05 ET
|
Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
13. November 2023 16:20 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
11. Oktober 2023 06:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
Senti Bio to Participate in Upcoming Investor Conferences
05. September 2023 08:30 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...